These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2005-003382-16 Pilot randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial). 2008-03-04 bad-data
Completed, but no date 2005-004569-40 Phase I and II perspective study with Citrate in Liposoma not Pegilate Doxorubicine TLC D-99 in association to Ifosfamide in patients with metastatic soft tissue sarcoma. bad-data
Completed, but no date 2006-001409-27 Pegfilgrastim versus filgrastim after high-dose chemotherapy followed by autologous peripheral blood stem cell, in patients with hematologic and solid tumors a randomized phase II study bad-data
Completed, but no date 2006-004429-27 Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma bad-data
Completed, but no date 2006-004437-15 FASE II PROSPECTIVE STUDY BAY-43-90006 IN ADVANCED, METASTATIC SOFT TISSUE SARCOMAS, AFTER ANTRACYCLINE-BASED THERAPY bad-data
Completed, but no date 2007-000758-30 Randomized continuation, dose escalation trial of Sorafenib in pts with advanced HCC with radiological progression on prior sorafenib treatment (Phase II study) bad-data
Completed, but no date 2007-003709-29 Prospective phase II trial evaluating efficacy of Trastuzumab therapy in HER2 FISH positive and/or HER2 mutation positive, pretreated, Non-Small Cell Lung Cancer patients (MO20509) bad-data
Completed, but no date 2007-004883-29 IGEV +/- Bortezomib (VelcadeTM) as induction before high dose consolidation in relapsed/ refractory Hodgkin’s lymphoma after first line treatment : a randomized phase II trial bad-data
Ongoing 2008-002126-12 A randomized phase II study of progression free survival comparing gemcitabine (1250 mg/m2 infusion) versus carboplatin (AUC5 infusion) plus alimta (500 mg/m2 infusion) as first-line chemotherapy in e... not-yet-due
Ongoing 2008-003202-33 Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome not-yet-due
Completed, but no date 2008-005714-46 BIOLOGICALS SUPPORTS STUDY IN RESECTIVE SURGERY OF PANCREATIC bad-data
Completed, but no date 2009-010672-16 PHASE II STUDY OF SUNITINIB IN METASTATIC RENAL CANCER WITH NON-CLEAR CELL HISTOLOGY bad-data
Completed, but no date 2009-011763-37 THE ANTI-ANGIOGENIC EFFECTS OF ADALIMUMAB IN CROHN`S DISEASE bad-data
Ongoing 2010-019683-37 PHASE II STUDY OF EVEROLIMUS IN PATIENTS WITH THYMOMA AND THYMIC CARCINOMA PREVIOUSLY TREATED WITH CHEMOTHERAPY not-yet-due
Completed, but no date 2010-022169-91 PHASE II STUDY WITH BENDAMUSTINE GEMCITABINE AND VINORELBINE (BeGEV) AS INDUCTION THERAPY IN RELAPSED/REFRACTORY HODGKIN’S LYMPHOMA PATIENTS BEFORE HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC... bad-data
Not reported 2010-023411-33 A phase II, randomized, double-blind, placebo controlled trial of Sorafenib as adjuvant treatment for hepatocellular carcinoma after TACE-based treatments. 2013-05-07 due-trials
Ongoing 2011-002122-43 Iron therapy in IBD patients with normal levels of haemoglobin and chronic fatigue not-yet-due
Ongoing 2011-003080-30 WEIGHT-ADJUSTED LOW MOLECOLAR WEIGHT HEPARIN IN RECURRENT IMPLANTATION FAILURE: A RANDOMIZED OPEN LABELED TRIAL not-yet-due
Ongoing 2012-003213-34 MEthylprednisoloneNacinHepatIcResections “MENHIR” not-yet-due
Ongoing 2012-005337-37 ANTI-MULLERIAN HORMONE (AMH) AS A MARKER OF OVARIAN RESERVE IN YOUNG BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY + GnRH ANALOGUE not-yet-due
Ongoing 2012-005338-13 OFATUMUMAB-BENDAMUSTINE FOR RELAPSED/REFRACTORY INDOLENT LYMPHOMA: A MULTICENTER PHASE 2 TRIAL not-yet-due
Not reported 2012-005578-79 A single-Arm Phase II Study of Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-resistant MET high subjects with locally advanced or metastatic colorectal cancer with wild-type KRAS 2016-11-04 due-trials
Ongoing 2012-005580-27 MULTI-CENTER, PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF HAPLOIDENTICAL BONE MARROW TRANSPLANTATION USING REDUCED INTENSITY CONDITIONING (RIC) REGIMEN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE, IN... not-yet-due
Ongoing 2014-001093-34 An Open-Label Phase II Study of regorafenib In Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND not-yet-due
Completed, but no date 2014-002579-27 Pilot study on the efficacy of golimumab in the induction and maintenance of clinical and endoscopic remission in patients with steroid-dependent ulcerative colitis. bad-data
Ongoing 2014-002876-10 A PHASE II STUDY OF THE COMBINATION OF GEMCITABINE AND IMATINIB MESYLATE IN PEMETREXED-PRETREATED PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA not-yet-due
Completed, but no date 2015-004543-40 A SINGLE ARM, PHASE II, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF VISMODEGIB AND RADIOTHERAPY IN PATIENTS WITH HIGH RISK OR LOCALLY ADVANCED BASAL CELL CARCINOMA NOT AMENABLE TO RADICAL S... bad-data
Ongoing 2016-004118-84 A multicenter, phase I-II trial of gemcitabine plus oxaliplatin and nbb-paclitaxel in subjects with advanced (unresectable or metastatic) biliary tract cancer (gallbladder cancer, cancer of the extrah... not-yet-due
Ongoing 2016-004510-99 PERFORMANCE OF BIORESORBABLE POLYMER-COATED EVEROLIMUS-ELUTING SYNERGY® STENT IN PATIENTS AT HIGH BLEEDING RISK UNDERGOING PERCUTANEOUS CORONARY REVASCULARIZATION FOLLOWED BY 1-MONTH DUAL ANTIPLATELET... not-yet-due
Ongoing 2017-004618-24 Evaluation of CardioprOtection by the use of betablocker Nebivolol in paTients with bReast cancer Or diffuse Large B cell lymphoma undergoing chemotherapy with anthracyclines: a randomized controlled ... not-yet-due